Business Context and Reporting Period
Company: Dermata Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2026
Reporting Period: Single event date (January 27, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in San Diego, CA. Its common stock (DRMA) and warrants (DRMAW) trade on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on a capital raising event.
- Previous Sales under Sales Agreement: $3,454,390 (shares of Common Stock sold pursuant to prior prospectus supplements).
- Additional Offering Capacity: $705,000 (increase in maximum aggregate offering amount).
Material Changes
The material change reported is an amendment to the Company's At The Market Offering Agreement (Sales Agreement) with H.C. Wainwright & Co., LLC, dated June 7, 2024.
- The Company filed a prospectus supplement to increase the maximum aggregate offering amount of shares of Common Stock issuable under the Sales Agreement by an additional $705,000.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the prospectus supplement to expand the offering capacity under the existing Sales Agreement. No specific operational guidance or future outlook is provided in this document.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard implications of a public offering. A legal opinion regarding the legality of the shares issuable under the Current Prospectus Supplement is filed as Exhibit 5.1.
Investor Verification Checklist
- Verify the total remaining capacity under the Sales Agreement after the $705,000 increase.
- Review the terms of the Sales Agreement with H.C. Wainwright & Co., LLC to understand commission structures and pricing mechanisms.
- Confirm the current share count and potential dilution impact of the additional $705,000 offering.
- Examine Exhibit 5.1 (Opinion of Lowenstein Sandler LLP) for any legal conditions attached to the offering.